A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 70 adults with nerve pain related to diabetes randomised at one centre. 66 completed.
- Dose used in the study
- 600 mg a day of Levagen+
- Duration
- 8 weeks
- What was measured
- Pain severity and interference on the BPI-DPN questionnaire, and pain characteristics on the NPSI; sleep, mood, blood markers and safety
What the authors reported
Total pain, pain interference and NPSI scores were lower than placebo from week 2 onward (P ≤ 0.001), with better sleep and mood scores and lower IL-6 and CRP. Adverse events were mild and short, and none led to withdrawal.
Limits of this study
One centre, 70 participants and 8 weeks. Most participants had type 2 diabetes, and blood sugar control varied. The authors called for larger studies. The funding statement was not visible on the page checked.
Source
doi:10.1007/s10787-022-01033-8
Entry checked against the article page at the publisher (Springer) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.